Raymond James Financial
IMMX icon

Raymond James Financial’s Immix Biopharma IMMX Stock Holding History

Raymond James Financial’s Portfolio IMMX Stock Details IMMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-525
Closed -$1.09K – 5803
2025
Q2 		$1.09K Buy
+525
New +$1.06K ﹤0.01% 6545

Other funds holding IMMX

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
UCFA
United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return
IW
Imprint Wealth Mount Pleasant, South Carolina $21.9M AUM

Raymond James Financial's IMMX Position: Q3 2025 in Review

Raymond James Financial sold out of Immix Biopharma (IMMX) in Q3 2025, closing a stake of 525 shares — an estimated $1.09K sold.

Raymond James Financial first reported a position in IMMX in Q2 2025 and held it in 1 quarter. The position peaked at $1.09K in Q2 2025. 31 funds tracked by Wall St. Rank hold IMMX as of Q3 2025.

  • Raymond James Financial reported no remaining Immix Biopharma position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 525 Immix Biopharma shares in Q3 2025, an estimated $1.09K.
  • Raymond James Financial first reported a position in Immix Biopharma in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's Immix Biopharma position peaked at $1.09K in Q2 2025.
  • 31 funds tracked by Wall St. Rank held Immix Biopharma as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.